Skip to main
PFE

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 21%
Buy 14%
Hold 57%
Sell 7%
Strong Sell 0%

Bulls say

Pfizer is a top pharmaceutical firm with strong commercial execution and a diverse product portfolio, generating $60 billion in annual sales. While their current growth drivers, such as Prevnar13 and Eliquis, have been successful, potential positive pipeline data is needed for post-LOE growth. However, recent concerns around sustainability integration and strategic actions, such as aggressive cost-cutting, may pose risks to the company's future performance.

Bears say

Pfizer is facing numerous challenges in its business which may negatively impact its stock performance. These include a declining revenue outlook due to lower COVID-19 estimates and increased competition for its top selling products, potential setbacks for its pipeline assets, and increased macro concerns. While the company has potential catalysts in the near future such as upcoming data releases for its pipeline assets and strong 1Q results that could lead to a potential guidance upgrade for 2026, there are still risks and uncertainties surrounding its long-term growth potential. With its slowest growth profile in the industry and a high number of LOEs approaching, Pfizer may face an earnings trough in 2028-29 with limited visibility for future growth.

Pfizer (PFE) has been analyzed by 14 analysts, with a consensus rating of Hold. 21% of analysts recommend a Strong Buy, 14% recommend Buy, 57% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Hold based on their latest research and market trends.

According to 14 analysts, Pfizer (PFE) has a Hold consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.93, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.93, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.